Aptly, clinical studies have shown that GRP78 cell-surface expression is correlated with poor prognosis in breast, liver, prostate, colon, and gastric cancers [20, 21]; that is due to high pathological grade, recurrence, and chemotherapy resistance. This evidence concerns the gene HSPA5 and gastric cancer.